Despite the success in B-cell malignancies, chimeric antigen receptor (CAR)-T cell therapies have not yet demonstrated consistent efficacy across all patients and tumor types, particularly against solid tumors. Higher rates of T cell exhaustion are associated with inferior clinical outcomes following CAR-T cell therapy, which is prevalent in solid tumors. T cell exhaustion may originate from persistent and chronic antigen stimulation by tumor cells that resist and/or evade T cell-mediated killing. We exploited CAR-T exhaustion with a classic negative feedback model (incoherent feedforward loop, IFFL) to investigate the balance between CAR-T cell activation and exhaustion under different antigen presentation dynamics. Built upon the experime...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies. However, ...
The clinical successes of chimeric antigen receptor (CAR)-T-cell therapy targeting cell surface anti...
International audienceInnovative immunotherapies based on immune checkpoint targeting antibodies and...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Chimeric antigen receptor (CAR) T-cell therapy has been successful in treating liquid tumors but has...
Chimeric antigen receptor (CAR) therapy is based on patient blood-derived T cells and natural killer...
Over the last decade remarkable progress has been made in enhancing the efficacy of CAR T therapies....
Abstract Intratumor heterogeneity of tumor clones and an immunosuppressive microenvironment in cance...
International audienceAdoptive transfer of T cells genetically engineered to express chimeric antige...
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological ...
Summary Co-stimulation is a fundamental component of T cell biology and plays a key...
Chimeric antigen receptor (CAR) T-cell therapy has been acclaimed as a revolution in cancer treatmen...
Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies. However, ...
The clinical successes of chimeric antigen receptor (CAR)-T-cell therapy targeting cell surface anti...
International audienceInnovative immunotherapies based on immune checkpoint targeting antibodies and...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Chimeric antigen receptor (CAR) T-cell therapy has been successful in treating liquid tumors but has...
Chimeric antigen receptor (CAR) therapy is based on patient blood-derived T cells and natural killer...
Over the last decade remarkable progress has been made in enhancing the efficacy of CAR T therapies....
Abstract Intratumor heterogeneity of tumor clones and an immunosuppressive microenvironment in cance...
International audienceAdoptive transfer of T cells genetically engineered to express chimeric antige...
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological ...
Summary Co-stimulation is a fundamental component of T cell biology and plays a key...
Chimeric antigen receptor (CAR) T-cell therapy has been acclaimed as a revolution in cancer treatmen...
Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies. However, ...
The clinical successes of chimeric antigen receptor (CAR)-T-cell therapy targeting cell surface anti...